Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 2

Pfizer Secures Up to $1.5 Billion From Blackstone for Obesity Drug

Nov 12, 2026
Pfizer has entered into a strategic funding agreement with Blackstone Life Sciences to support the development of its experimental obesity treatment, berobenatide. Under the…
Read More...

Biomatter Raises $18 Million to Expand AI-Powered Enzyme Design

Nov 12, 2026
Biomatter, a Lithuania-based biotechnology company, has raised $18 million in an oversubscribed Series A funding round to expand its artificial intelligence (AI)-powered enzyme design…
Read More...

Bristol Myers Squibb Combines Research and Development Under New Leadership

Nov 12, 2026
Bristol Myers Squibb (BMS) has announced plans to bring its research and development operations together under a single organisation to accelerate drug discovery and strengthen its…
Read More...

Neurosterix Raises $105 Million to Advance Schizophrenia Drug

Nov 12, 2026
Neurosterix has raised $105 million in Series B financing to advance its experimental treatments for schizophrenia and other neuropsychiatric disorders. The funding will primarily…
Read More...

Promega and BrainXell Partner to Advance Neuroscience Drug Discovery

Nov 12, 2026
Promega Corporation has signed a licensing agreement with BrainXell to bring its NanoLuc, NanoBiT and HaloTag technologies into human stem cell-based models used for neurological…
Read More...

Takeda Launches ORZEYFUL for Narcolepsy Type 1 in the US

Nov 12, 2026
Takeda has launched ORZEYFUL (oveporexton) in the United States for adults living with narcolepsy type 1 (NT1), making the first-in-class orexin receptor treatment available by…
Read More...

Charles River Expands Global Microbial Solutions Operations

Nov 12, 2026
Charles River Laboratories has announced new investments across its global Microbial Solutions business to increase manufacturing capacity, improve customer support and strengthen…
Read More...

ChronicleBio and Prolong Test PP-007 for Chronic Fatigue Syndrome

Nov 12, 2026
ChronicleBio and Prolong Pharmaceuticals have announced a partnership to evaluate PP-007 as a potential treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The…
Read More...

Lilly Reports Positive Results for Taltz and Zepbound Combination in Psoriatic Arthritis

Nov 12, 2026
Eli Lilly has reported positive one-year results from a Phase 3b clinical trial evaluating the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults living with active…
Read More...

Oyster Therapeutics Raises $60 Million to Develop Alzheimer’s Drugs

Nov 12, 2026
Oyster Therapeutics, formerly known as Kesmalea Therapeutics, has raised $60 million in Series A financing to advance its next-generation targeted protein degradation programmes for…
Read More...
Previous 1 2 3 4 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.